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ABSTRACT 
Backgroud and objective: To evaluate onset and stability of thera-
peutic effect of 4-week melatonin treatment for chronic sleep onset in-
somnia in elementary school-aged children. Methods: Retrospective 
analysis of unpublished data obtained from two previously published 
randomized, double-blind and placebo-controlled trials on melatonin 
treatment efficacy for childhood insomnia in children with chronic 
sleep onset insomnia, age �-12 years (n=49). Intervention consisted 
of placebo (n=25) or melatonin 5 mg (n=24) administered at � (n=9) 
or 19h (n=40) during four weeks. Collected data were “light-out 
time”, “sleep onset latency”, “sleep onset”, “total sleep time”, “wake-
up time”, and subjective sleep measures recorded in a diary. Results: 
Melatonin treatment showed a phase-advance of lights out of 21h15 
(1.05) to 20h28 (1.07); sleep onset advanced from 22h05 (0.93) to 
20h45 (1.09) and sleep latency decreased from 53 (39) to 18 minutes 
(1�). After the 4-week trial period, these values were 20h44 (1.27), 
21h09 (1.33), 25 minutes (39). Conclusions: Melatonin advances 
sleep latency and sleep onset and increases total sleep time starting 
right from the first treatment night in children with chronic sleep on-
set insomnia. Evidence is provided that the onset of melatonin treat-
ment effect can be expected within a few days after commencement 
and, then, remains stable.
Keywords: Sleep initiation and maintenance disorders/drug therapy; 
Melatonin/therapeutic use; Education, primary and secondary; Child
RESUMO
Objetivo: Avaliar o início dos efeitos e a estabilidade do tratamento 
para insônia de início do sono com melatonina por quatro semanas 
em crianças cursando escola primária. Métodos: Análise retrospec-
tiva de dados inéditos obtidos de dois ensaios randomizados, duplo-
cegos e controlados por placebo sobre a eficácia do tratamento da 
melatonina para insônia na infância em crianças com início de in-
sônia crônica com idades entre � e 12 anos (n=49). A intervenção 
consistiu em placebo (n=25) ou melatonina 5 mg (n=24) ministra-
dos às 18 (n=9) ou 19h (n=40) durante quatro semanas. Os dados 
coletados foram “horário em que as luzes foram apagadas”, “latência 
até o início do sono”, “início do sono”, “tempo total de sono”, “ho-
rário de despertar” e medidas subjetivas do sono registrados em um 
diário. Resultados: O tratamento com melatonina evidenciou fase 
adiantada quando as luzes estavam apagadas das 21h15 (1.05) às 
20h28 (1.07); o início do sono avançou das 22h05 (0.93) às 20h45 
(1.09) e latência ao sono diminuiu de 53 (39) para 18 minutos (1�). 
Ao término das quatro semanas, esses valores passaram a ser 20h44 
(1,27), 21h09 (1.33), 25 minutos (39). Conclusões: A melatonina 
adianta a latência ao sono e ao início do sono aumentando o tempo 
total de sono a partir da primeira noite em crianças que sofrem de 
insônia de início de sono crônica. As evidências demonstram que o 
efeito pelo tratamento de melatonina para o início do sono pode ser 
esperado dentro de alguns dias após o início do tratamento e, então, 
se mantém estável.
Descritores: Dist�rbios do início e da manutenção do sono/qui-
mioterapia; Melatonina/uso terapêutico; Ensino fundamental e médio; 
Criança
INTRODUCTION
Sleep onset insomnia is a highly prevalent disorder among 
school-age children. A chronic and severe presentation lead-
ing to long-term sleep deprivation can seriously affect a 
child’s physical and mental development. We have previous-
ly shown in two randomized, double-blind and placebo-con-
trolled studies in elementary school children with chronic 
sleep onset insomnia suggestive of delayed sleep phase dis-
order that melatonin (5 mg) advanced sleep-wake rhythm 
and lengthened total sleep duration (1,2). However, the data 
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published merely included treatment measurements per-
formed within the fourth week. We have further analyzed 
these findings by considering all data obtained from Day 1 
to Week 4 in the treatment period, instead of focusing on 
endpoint data. Knowledge of the time-course and stability 
of the treatment effects during therapy initiation is clinical-
ly relevant for clinicians and researchers for this can prevent 
unnecessary long administration of melatonin, for example, 
when the appropriate dose of melatonin needs to be deter-
mined (3). If, during the initiation phase, the dose effect is 
evaluable after days instead of weeks, the initiation phase of 
effective therapy can be shortened from weeks to days.
While long-term treatment efficacy has already been es-
tablished by several research groups (4,5), and direct soporific 
effects of melatonin were recently described in the context of 
sedation for electroencephalogram (EEG) recording (�), this 
is the first study to report on the time-course and stability of 
melatonin treatment effects for insomnia treatment.
This study’s aim was to evaluate the acute, wanted effects 
of melatonin administration to children with sleep onset in-
somnia. The long-term safety, especially addressing the in-
fluence on puberty onset, is a still to be sufficiently answered 
issue. For this population, long-term effects, including the 
adverse events, are described elsewhere (7).
METHODS
Subjects were elementary school children with chronic sleep 
onset insomnia, who participated in one of two randomized 
placebo-controlled studies published earlier (1,2). They were 
aged � to 12 years and in otherwise good general health; 
their sleep problems were not related to any other pathology 
than attention deficit hyperactivity disorder (ADHD) and 
suggestive of delayed sleep phase disorder. Other sleep pa-
thology was excluded by ambulatory polysomnography with 
24-hour cassette electroencephalography at the child’s home 
and parental report.
The institutional review board on human research ap-
proved both studies and informed consent was obtained from 
the parents of all participants. A 1-week baseline phase pre-
ceded a 4-week treatment phase. Melatonin immediate re-
lease tablets (5 mg) or identical-looking placebo were given 
at 18h (melatonin: n=19; placebo: n=19) daily in the first 
study (1) and at 19h (melatonin: n=35; placebo: n=3�) in the 
second (2). Sleep onset insomnia was defined as (a) complaints 
of sleep-onset problems expressed by parents and/or child; (b) 
occurrence on at least four days/week for longer than one year; 
(c) average sleep onset later than 20h30 for children at age � 
years and for older children 15 minutes later per year; and (d) 
average sleep onset latency exceeding 30 minutes. Exclusion 
criteria were disturbed sleep architecture as measured by am-
bulatory  polysomnography, and sleep maintenance insomnia 
(one awakening>30 minutes or two or more awakenings >5 
minutes summing up to at least 40 minutes, occurring on one 
or more nights a week, for a period of at least 4 weeks preced-
ing the start of the trial). Further exclusion criteria were men-
tal handicap, severe learning disabilities, liver disease, renal 
failure, chronic pain, and severe neurological or psychiatric 
disorders. Finally, any prior use of melatonin, use of hypnot-
ics, antidepressants, and neuroleptics was exclusion criterion. 
Allowed medications were methylphenidate and salbutamol 
by inhalation.
In the present paper, a sleep log was considered incom-
plete when it did not cover the entire four-week treatment 
period (which is the period of interest in the present study). 
This is in contrast to the previously published articles, when 
it was considered incomplete when there were no data of the 
fourth treatment week (which was the period of interest in 
the previous studies). This complete coverage of the four-
week treatment was accomplished in 49% of the originally 
included participants. The 51% missing data during the 
first three treatment weeks is due to the fact that the deci-
sion to record sleep data over the entire four-week trial pe-
riod (instead of during the fourth treatment week only) was 
made at a time when both trials were already in progress. 
Parents were asked to complete the following param-
eters in sleep logs daily: light-out time (time when the 
light was turned off before sleeping), sleep onset time (es-
timated time when the child fell asleep, assessed by check-
ing on the child through listening or watching every ten 
minutes, as noninvasive as possible), wake-up time (esti-
mated time of waking up), get up time (time of getting 
out of bed). Means and standard deviations were calculated 
over the baseline week and each treatment week, resulting 
in five mean (SD) values per parameter. Intra, intergroup 
and interaction effects were tested using multivariate anal-
yses of variance (α≤0.05). Differences in means for four 
sleep parameters, i.e. sleep onset time , sleep onset latency, 
wake-up time and total sleep time were tested for each of 
the 34 pairs of consecutive days (1st and 2nd night… 34th 
and 35th night) using the Wilcoxon signed-rank test. To 
account for multiple comparisons the α-level was set at 
0.00147 (0.05 was divided by the number of comparisons: 
34). Besides the mean values above mentioned, we tried 
to rate therapy success with an individual parameter. We 
defined as criterion for successful therapy the number of 
patients with a decreased sleep onset latency of at least 25 
minutes (being the standard deviation in sleep onset la-
tency of both groups and even more important: a decrease 
expected to be experienced as a clinically relevant relief of 
sleep onset insomnia). We assessed this parameter for both 
groups (melatonin and placebo) after one, two, three and 
four weeks of therapy compared to baseline.
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RESULTS
In the first study (1), there were 38 participants, of which 
33 sleep logs were available on the fourth treatment week; 
however of those 33 only 9 sleep logs were completed dur-
ing the entire four-week treatment period. In the other paper 
(2), there were �2 participants, of which 55 sleep logs were 
completed during fourth treatment week; however, only 40 
sleep logs were completed during the entire four-treatment 
weeks � data are used for the present study.
Of the total sample included in the present study (n=49), 
25 children (17 male and 8 female; � of trial (1) and 19 of 
trial (2)) were assigned to melatonin treatment and 24 chil-
dren (19 male and 5 female; 3 of trial (1) and 21 of trial (2)) 
to placebo.  
Figure 1 depicts the mean values for lights out and 
sleep onset time over the course of treatment. As can be 
seen, robust phase advances occur within the first week of 
melatonin treatment, after which the values remain stable 
except for a slight delay within the third treatment week. 
The convergent direction of the lights out and sleep onset 
lines indicate a decrease of sleep onset latency within the 
first treatment week. 
Responders, defined as patients with a 25-minute decrease 
in sleep onset latency, were compared between weeks and 
groups, the group effect tested by type III between-subjects 
tests. During the 1st treatment week, in the melatonin group, 
14 patients responded with a >25-minute decrease in mean 
sleep onset latency, while this was 4 in the Placebo Group 
(F=9.379; p=0.004). Responders in the 2nd week were 1� 
patients in Melatonin and 5 in Placebo Group (F=11.035; 
p=0.002); 13 in Melatonin and 4 in Placebo in the 3rd week 
(F=7.505; p=0.009), and 13 in Melatonin and 7 in Placebo 
in the 4th week (F=2.�79; p=0.108). In the Melatonin Group, 
11 patients met this criterion for success for each of the 4 
weeks, against 1 in Placebo (F=10.177; p=0.003). 
It is noteworthy that two patients in the Melatonin 
Group had any response and one patient in the Placebo 
Group had a consistent high response.
Figure 3 depicts wake-up time over the course of treat-
ment, variation which shows an advanced phase that is most 
robust in the first treatment week and gradually stabilizes in 
the next treatment weeks. Values in placebo show a continu-
ing irregular pattern.
Figure 2: Mean sleep onset latency in Week 1 (i.e. baseline) and Week 2 
to 5 (i.e. intervention).
Figure 3: Mean wake-up time in Days 1 to 7 (i.e. baseline) and Days 8 to 
35 (i.e. intervention).
Figure 1: Mean light-out time and sleep onset time Day 1-7 (i.e. baseline) 
and Day 8-35 (i.e. intervention).
This sleep onset latency is of importance, since this 
parameter clearly demonstrates the trouble falling asleep 
for children sent to bed. Mean (± SD) sleep onset latency 
changed in the Treatment Group from baseline 53 (±39) to 
18 minutes (±1�) in treatment Week 1 to 1� minutes (±17) 
in Week 3, to 19 minutes (±21) in Week 4 and 25 minutes 
(±38) in Week 5. 
On the contrary, lights out, sleep onset and therefore 
sleep onset latency did not significantly change in the Pla-
cebo Group, as illustrated by the white gap in Figure 1 (�2 
(±43), 55 (±48), 58 (±47), �0 (±51) and 49 (±52) minutes 
in the last treatment week) (Figure 2).
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Results of multivariate analyses of variance are sum-
marized in Table 1. The results show that pretreatment to 
treatment changes of sleep onset, sleep latency, total sleep 
time light-out and wake-up time are significantly different 
whilst melatonin treatment as compared to placebo treat-
ment (i.e. Week 1 versus later * treatment group). Further 
analysis shows that the difference in pretreatment to treat-
ment changes of these sleep parameters are already signifi-
cant after one week of treatment (i.e. Week 1 versus Week 2 
* treatment group), except for get up time. 
Main effects of  week number and treatment group on 
total sleep time are significant when the interaction is not. 
This means that the Melatonin Group exceeds the Placebo 
Group on the average, but that the trend over the weeks does 
not differ between the two groups. Compared to placebo, 
melatonin resulted in a significantly larger decrease in chil-
dren’s perceived difficulties in falling asleep, from baseline 
to later weeks as well as from baseline to the second week. 
As compared to placebo, the Melatonin Group showed a 
significantly different change in feeling rested in the morn-
ing from baseline to the first treatment week. However, this 
effect did not sustain during the four-week treatment pe-
riod. No significant effects were found for mood during the 
evening, mood at daytime and perceived sleep quality (not 
shown). 
Finally, Table 2 shows the change in sleep latency, sleep 
onset time, and total sleep time from the final baseline night 
to the first treatment night within the Melatonin Treatment 
Group. The results reveal significant improvements in all 
three parameters during this first treatment night. The 
Wilcoxon signed-rank test revealed that for the 34 pairs of 
Parameter/type ‘Exposure’ variablea df1 df2 F p-value Form of the function
Sleep onset time
Main  Week number 4 44 25.22� < 0.001 Advances
Week number*treatment group 4 44 1�.000 < 0.001 Advances
Treatment group 1 47 1�.511 < 0.001 Advances
Time contrasts Week 1 versus later*treatment group  1 47 39.311 < 0.001 Advances
Week 1 versus Week 2*treatment group 1 47 30.18� < 0.001 Advances
Sleep latency
Main  Week number 4 44 9.011 < 0.001 Decreases
  Week number*treatment group 4 44 7.1�8 < 0.001 Decreases
  Treatment group 1 47 19.240 < 0.001 Decreases
Time contrasts  Week 1 versus later*treatment group 1 47 19.489 < 0.001 Decreases
  Week 1 versus Week 2*treatment group 1 47 18.344 < 0.001 Decreases
Total sleep time
Main  Week number 4 44 11.203 < 0.001 Increases
 Week number*treatment group 4 44 2.523 0.054
  Treatment group 1 47 1�.284 < 0.001 Increases
Time contrasts  Week 1 versus later*treatment group 1 47 7.375 0.009 Increases
Week 1 versus Week 2*treatment group 1 47 8.07� 0.007 Increases
Difficulty falling asleep
Main Week number 4 44 20.095 < 0.001 Decreases
  Week number*treatment group 4 44 7.1�8 < 0.001 Decreases
  Treatment group 1 47 29.833 < 0.001 Decreases
Time contrasts  Week 1 versus later*treatment group 1 47 18.853 < 0.001 Decreases
  Week 1 versus Week 2*treatment group 1 47 18.348 < 0.001 Decreases
Feeling rested (morning)
Main  Week number 4 44 4.925 0.002 Increases
  Week number*treatment group 4 44 3.22� 0.021 Increases
  Treatment group 1 47 7.108 0.010 Increases
Time contrasts  Week 1 versus later*treatment group 1 47 0.849 0.3�2
  Week 1 versus Week 2*treatment group 1 47 5.4�5 0.024 Increases
Table 1: Results of multivariate analyses of variance for sleep parameters
Sleep parameter z p-value
Sleep latency
Difference in means of 7th night - 8th night  -3.92 0.00009
Sleep onset time
Difference in means of 7th night - 8th night  -3.95 0.00008
Total sleep time
Difference in means of 7th night - 8th night  -3.77 0.0001�
Table 2: Results of the first treatment night in the melatonin treatment 
group
a: week number and week number*treatment group effects tested by Wilks’ lambda; treatment group effect tested by type III between-subjects test.
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consecutive daily means for sleep latency, sleep onset time 
and total sleep time the difference between consecutive pairs 
of nights was only statistically significant (α-level set at 
0.00147) for the change over the final baseline night to the 
first treatment night in the Melatonin Treatment Group. 
Differences between consecutive night pairs of the four 
parameters within the Placebo Group were all statistically 
non-significant. 
DISCUSSION
This paper is a further analysis of data from our two previous 
publications, and we have now found that effects of melato-
nin on sleep latency, sleep onset time and total sleep time 
occur from the first night of treatment. These effects were 
stable during a four-week intervention period. Melatonin 
initially also improved feeling rested in the morning, which 
however did not sustain during intervention. 
Individual results for sleep onset latency and using this 
result as a criterion for successful therapy corroborate the 
mean study population results, since the variance of sleep 
measures (sleep onset and wake-up time in particular) is 
large in a population with varying sleep needs (age � to 
12 years) and this variance is much smaller in the mean 
calculated measure sleep onset latency. What strikes in the 
responders results is that most responders in the Melato-
nin Group are consistent during the four treatment weeks 
(11), as in the Placebo Group this was only applicable for 
one patient. 
In contrast to the Melatonin Group (which showed im-
mediate decrease of sleep onset latency starting from Treat-
ment Day 1), the Placebo Group showed decreasing sleep 
onset latency values from Week 1 to Week 4, although not 
statistically significant. One reason for this finding could be 
the conditioning effect of parents checking on the child ev-
ery ten minutes. If children are anxious, knowing and hav-
ing a parent come in and check on them in set intervals 
may have a curing effect on their insomnia. It is a common 
finding in randomized clinical trials studying treatment ef-
fect in insomniacs that placebo produces significant changes 
on self-reported sleep measures (8). However, in our studies, 
sleep measures did not significantly change during placebo 
treatment, with one exception. This might be explained by 
the fact that the sleep measures were not assessed by the 
patients themselves.
There are several limitations of this study; one of which 
is that we did not assess sleep objectively by means of poly-
somnography or actigraphy. However, parents of sleep-dis-
turbed infants have shown to be accurate reporters of acti-
graphically assessed sleep onset and sleep duration (9). 
We used the data of two studies, with different tim-
ing of melatonin administration, although the two 
subsets show very similar characteristics of sleep-wake 
rhythm and endogenous melatonin onset. Moreover, the 
effect of melatonin on sleep parameters did not differ 
between the two studies (1-2). Melatonin treatment for 
chronic insomnia in children has been criticized in the 
Netherlands. Jenni (10) stressed that cultural variation 
and developmental variation and biological variability 
of sleep behavior among normal healthy children should 
be taken into account. However, in our studies we did 
not include healthy children, but children with chronic 
complaints of insomnia who showed impaired general 
health and quality of life likely due to their insomnia 
problems (11).
To conclude, the results presented here provide proof that 
onset of melatonin treatment effect can be expected within 
a few days and this effect remains stable in the weeks after 
that, in addition to the earlier evidence (1,2,12) that melatonin 
is an effective treatment for sleep onset insomnia in children 
with late melatonin onset.
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